AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Mitochondrial Disease Therapies Market 2019, with Forecasts to 2030 - ResearchAndMarkets.com

October 11, 2019

DUBLIN--(BUSINESS WIRE)--Oct 11, 2019--

The “Mitochondrial Disease Therapies Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering.

Mitochondrial diseases are characterized by chronic, genetic and progressive medical symptoms that arise due to inherited or spontaneous mutations in mitochondrial DNA, or in some cases, nuclear DNA, which adversely alter the function of mitochondria. Such clinical conditions are rare and are known to affect multiple parts of the body, including neurons and nerves, kidneys, heart, liver, eyes, ears, and pancreas. It is worth highlighting that over 300 mutations have been identified and are associated with various mitochondrial diseases. Examples of diseases that are caused due to mutations in mitochondrial DNA include Leber’s hereditary optic neuropathy (LHON), Leigh syndrome, mitochondrial DNA depletion syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and myoclonic epilepsy with ragged red fibers (MERRF).

In the US, mitochondrial diseases are known to annually affect 1 in 5,000 individuals. It is also estimated that 1,000-4,000 children are born with a mitochondrial disease every year, in the same region. Primary mitochondrial diseases are usually difficult to diagnose. In many cases, clinicians and medical professionals are compelled to use the term possible mitochondrial disease, indicating that based on the presenting symptoms they suspect a patient to be suffering from a mitochondrial disease. However, they are unable to confirm the condition via genetic diagnosis. Such instances are further complicated by the aforementioned uncertainty, leading to delays in treatment and subsequent deterioration in the patient’s quality of life. Currently, several industry stakeholders are engaged in efforts to develop disease-modifying interventions for treating different mitochondrial diseases, in addition to drug/therapy candidates that offer symptomatic relief. There are several non-profit organizations that have been established across the globe to support individuals suspected/diagnosed with mitochondrial diseases and also fund research / clinical studies being conducted for the treatment of such conditions. In the coming years, the market is anticipated to grow at a significant pace as more novel therapy solutions are approved by regulatory authorities and enter the market.

The Mitochondrial Disease Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of therapeutics designed to treat mitochondrial diseases. It features an in-depth analysis, highlighting the capabilities of stakeholder companies/organizations engaged in this domain. In addition to other elements, the study includes:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/uadrs2

View source version on businesswire.com:https://www.businesswire.com/news/home/20191011005405/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 10/11/2019 11:30 AM/DISC: 10/11/2019 11:30 AM

http://www.businesswire.com/news/home/20191011005405/en